Epimacular Brachytherapy, utilizing the VIDION® product line, is the only current radiation treatment for wet AMD that has been evaluated in a Phase 3 clinical study.
(PRWEB) November 05, 2012
NeoVista, Inc. has launched a revised company website. The revised website now provides patients and care givers with contact information for hospitals outside of the United States that offer Epimacular Brachytherapy (EMBT) as an adjunct treatment to anti-VEGF injections for wet age-related macular degeneration.
Epimacular Brachytherapy received commercial clearance in 2009, in all markets where CE mark designation is recognized. EMBT is currently offered in Germany, Austria, Israel, Norway, Italy, and the United Kingdom. In addition to these countries, further openings are expected in the coming months in Poland, Spain, South Africa, Canada, and Austria.
John N. Hendrick, President and CEO of NeoVista, stated, “Since the international launch of Epimacular Brachytherapy in 2009, we continue to receive frequent communication from patients around the world seeking relief from intraocular injections. In previous clinical trials, EMBT was shown to be effective in reducing the frequency of injections, while also protecting vision. Outside of clinical trials, more than 200 patients have now received Epimacular Brachytherapy as an adjunct therapy, and the results to date have been quite remarkable.”
“Epimacular Brachytherapy, utilizing the VIDION® product line, is the only current radiation treatment for wet AMD that has been evaluated in a Phase 3 clinical study. We now await the results of a second Phase 3 clinical study that was sponsored by King’s College, London, England, through support from the National Health Service. We expect to learn the results of this study in the early part of 2013 and we remain cautiously optimistic. With positive clinical outcomes, we envision governments will quickly adopt EMBT as a standard treatment for wet AMD, thus negating the current financial impact on patients.”
About NeoVista, Inc.
NeoVista, Inc. is a privately held medical device company based in Newark, California. The company's first commercial product, the VIDION® ANV® Therapy System, is cleared for commercial sale in all markets that accept a CE Mark. For more information about the company, or this novel neovascular AMD therapy, please visit the company's Web site at http://www.neovistainc.com.